The historical rank and industry rank for BioRestorative Therapies's Net Margin % or its related term are showing as below:
BRTX'
s Net Margin % Range Over the Past 10 Years
Min: -96310.87 Med: -11272.59 Max: -2239.15
Current: -3088.27
BRTX's Net Margin % is ranked worse than 86.8% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs BRTX: -3088.27
BioRestorative Therapies (NAS:BRTX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioRestorative Therapies Net Margin % Related Terms
BioRestorative Therapies Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioRestorative Therapies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (BRTX) has a Net Margin % of -9,365.22% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #822 out of 947 companies in the Biotechnology industry, placing it in the top 86.8%.
Is BioRestorative Therapies' Net Margin % too high?
BioRestorative Therapies' current Net Margin % is -9,365.22%. Based on the distribution chart, BioRestorative Therapies ranks #822 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Net Margin % compare to KPRX and INTS?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #822 out of 947 companies for Net Margin %. This places BioRestorative Therapies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current Net Margin % is -9,365.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (BRTX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.52, compared to a current price of $0.40 — trading 73.9% below its estimated fair value. The current Net Margin % is -9,365.22%. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioRestorative Therapies (BRTX), the current Net Margin % is -9,365.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (BRTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of $0.40 is trading 73.9% below its estimated GF Value™ of $1.52.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for BRTX:
Net Margin %: -9,365.22%
GF Value™: $1.52 vs. price of $0.40 (73.9% below fair value)
No single metric tells the full story. See the BRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score
Get the complete analysis for BRTX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRTX has been successfully added to your 
